Lindsey E. Cook
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lindsey E. Cook has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Deborah J. Lenschow
Departments of Medicine, Washington University School of Medicine, Saint Louis, MO, USA
4 shared publications Alissa R. Young
Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA
3 shared publicationsKristen Monte
Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
3 shared publications- Marissa C. Locke
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA
2 shared publications - Matthew L. Hedberg
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 415 Curie Blvd, Philadelphia, PA 19104, USA
2 shared publications - Michael S. Diamond
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
2 shared publications
Latest Publications
- 12 January 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (1) , e0114321
Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis
Chikungunya virus (CHIKV) is a reemerging global pathogen with no effective vaccine or antiviral treatment for acute or chronic disease, and the mechanisms underlying chronic disease manifestations remain poorly defined. The significance of our research is in defining IFN-α, but not IFN-β, as an important host regulator of chronic CHIKV pathogenesis that acts within the first 48 h of infection to limit persistent viral RNA and the number of cells that survive CHIKV infection 1 month postinfection.
- 12 January 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (1) , e0114321
Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis
Chikungunya virus (CHIKV) is a reemerging global pathogen with no effective vaccine or antiviral treatment for acute or chronic disease, and the mechanisms underlying chronic disease manifestations remain poorly defined. The significance of our research is in defining IFN-α, but not IFN-β, as an important host regulator of chronic CHIKV pathogenesis that acts within the first 48 h of infection to limit persistent viral RNA and the number of cells that survive CHIKV infection 1 month postinfection.
- 12 December 2019
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (1)
Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation
Type I interferons (IFNs) possess a range of biological activity and protect against a number of viruses, including alphaviruses. Despite signaling through a shared receptor, there are established biochemical and functional differences among the IFN subtypes. The significance of our research is in demonstrating that IFN-α and IFN-β both have protective roles during acute chikungunya virus (CHIKV) infection but do so by distinct mechanisms. IFN-α limits CHIKV replication and dissemination, whereas IFN-β protects from CHIKV pathogenesis by limiting inflammation mediated by neutrophils. Our findings support the premise that the IFN subtypes have distinct biological activities in the antiviral response.
- 12 December 2019
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (1)
Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation
Type I interferons (IFNs) possess a range of biological activity and protect against a number of viruses, including alphaviruses. Despite signaling through a shared receptor, there are established biochemical and functional differences among the IFN subtypes. The significance of our research is in demonstrating that IFN-α and IFN-β both have protective roles during acute chikungunya virus (CHIKV) infection but do so by distinct mechanisms. IFN-α limits CHIKV replication and dissemination, whereas IFN-β protects from CHIKV pathogenesis by limiting inflammation mediated by neutrophils. Our findings support the premise that the IFN subtypes have distinct biological activities in the antiviral response.
- Open Access
- 29 August 2019
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 15 (8) , e1007993
Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA
Chikungunya virus (CHIKV) is an arthritogenic alphavirus that acutely causes fever as well as severe joint and muscle pain. Chronic musculoskeletal pain persists in a substantial fraction of patients for months to years after the initial infection, yet we still have a poor understanding of what promotes chronic disease. While replicating virus has not been detected in joint-associated tissues of patients with persistent arthritis nor in various animal models at convalescent time points, viral RNA is detected months after acute infection. To identify the cells that might contribute to pathogenesis during this chronic phase, we developed a recombinant CHIKV that expresses Cre recombinase (CHIKV-3ʹ-Cre). CHIKV-3ʹ-Cre replicated in myoblasts and fibroblasts, and it induced arthritis during the acute phase in mice. Importantly, it also induced chronic disease, including persistent viral RNA and chronic myositis and synovitis similar to wild-type virus. CHIKV-3ʹ-Cre infection of tdTomato reporter mice resulted in a population of tdTomato+ cells that persisted for at least 112 days. Immunofluorescence and flow cytometric profiling revealed that these tdTomato+ cells predominantly were myofibers and dermal and muscle fibroblasts. Treatment with an antibody against Mxra8, a recently defined host receptor for CHIKV, reduced the number of tdTomato+ cells in the chronic phase and diminished the levels of chronic viral RNA, implicating these tdTomato+ cells as the reservoir of chronic viral RNA. Finally, isolation and flow cytometry-based sorting of the tdTomato+ fibroblasts from the skin and ankle and analysis for viral RNA revealed that the tdTomato+ cells harbor most of the persistent CHIKV RNA at chronic time points. Therefore, this CHIKV-3ʹ-Cre and tdTomato reporter mouse system identifies the cells that survive CHIKV infection in vivo and are enriched for persistent CHIKV RNA. This model represents a useful tool for studying CHIKV pathogenesis in the acute and chronic stages of disease. Chikungunya virus (CHIKV) is spread by mosquitoes and causes severe joint and muscle pain. Approximately 30 to 60 percent of people infected with CHIKV continue to experience joint pain for months to years after the initial infection. However, the cause of this persistent joint pain is unclear, as replicating virus cannot be detected during the chronic phase. We have developed a reporter virus system to permanently mark cells infected by CHIKV. Using this system, we show in mice that marked cells surviving CHIKV infection are present for at least 112 days after initial virus inoculation. The marked cells are a mixture of muscle and skin cells. We also show that treatment of mice with an antibody that blocks receptor engagement and CHIKV infection reduces the number of marked cells in the muscle and skin. Finally, we have demonstrated that surviving tdTomato+ cells contain most of the persistent CHIKV RNA. This reporter virus system represents a useful tool for identifying and isolating cells that harbor chronic viral RNA in order to study chronic disease pathogenesis.
- 29 August 2019
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 15 (8) , e1007993
Open AccessDermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA
Chikungunya virus (CHIKV) is an arthritogenic alphavirus that acutely causes fever as well as severe joint and muscle pain. Chronic musculoskeletal pain persists in a substantial fraction of patients for months to years after the initial infection, yet we still have a poor understanding of what promotes chronic disease. While replicating virus has not been detected in joint-associated tissues of patients with persistent arthritis nor in various animal models at convalescent time points, viral RNA is detected months after acute infection. To identify the cells that might contribute to pathogenesis during this chronic phase, we developed a recombinant CHIKV that expresses Cre recombinase (CHIKV-3ʹ-Cre). CHIKV-3ʹ-Cre replicated in myoblasts and fibroblasts, and it induced arthritis during the acute phase in mice. Importantly, it also induced chronic disease, including persistent viral RNA and chronic myositis and synovitis similar to wild-type virus. CHIKV-3ʹ-Cre infection of tdTomato reporter mice resulted in a population of tdTomato+ cells that persisted for at least 112 days. Immunofluorescence and flow cytometric profiling revealed that these tdTomato+ cells predominantly were myofibers and dermal and muscle fibroblasts. Treatment with an antibody against Mxra8, a recently defined host receptor for CHIKV, reduced the number of tdTomato+ cells in the chronic phase and diminished the levels of chronic viral RNA, implicating these tdTomato+ cells as the reservoir of chronic viral RNA. Finally, isolation and flow cytometry-based sorting of the tdTomato+ fibroblasts from the skin and ankle and analysis for viral RNA revealed that the tdTomato+ cells harbor most of the persistent CHIKV RNA at chronic time points. Therefore, this CHIKV-3ʹ-Cre and tdTomato reporter mouse system identifies the cells that survive CHIKV infection in vivo and are enriched for persistent CHIKV RNA. This model represents a useful tool for studying CHIKV pathogenesis in the acute and chronic stages of disease. Chikungunya virus (CHIKV) is spread by mosquitoes and causes severe joint and muscle pain. Approximately 30 to 60 percent of people infected with CHIKV continue to experience joint pain for months to years after the initial infection. However, the cause of this persistent joint pain is unclear, as replicating virus cannot be detected during the chronic phase. We have developed a reporter virus system to permanently mark cells infected by CHIKV. Using this system, we show in mice that marked cells surviving CHIKV infection are present for at least 112 days after initial virus inoculation. The marked cells are a mixture of muscle and skin cells. We also show that treatment of mice with an antibody that blocks receptor engagement and CHIKV infection reduces the number of marked cells in the muscle and skin. Finally, we have demonstrated that surviving tdTomato+ cells contain most of the persistent CHIKV RNA. This reporter virus system represents a useful tool for identifying and isolating cells that harbor chronic viral RNA in order to study chronic disease pathogenesis.
- 1 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (375)
Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis
Combination therapy with CTLA4-Ig and an antiviral human monoclonal antibody controls chikungunya virus arthritis in mice.
- 1 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (375)
Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis
Combination therapy with CTLA4-Ig and an antiviral human monoclonal antibody controls chikungunya virus arthritis in mice.
- Open Access
- 3 April 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 1-13
Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation
TH1 and TH17 cells mediate neuroinflammation in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Pathogenic TH cells in EAE must produce the pro-inflammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF). TH cell pathogenicity in EAE is also regulated by cell-intrinsic production of the immunosuppressive cytokine interleukin 10 (IL-10). Here we demonstrate that mice deficient for the basic helix–loop–helix (bHLH) transcription factor Bhlhe40 (Bhlhe40−/−) are resistant to the induction of EAE. Bhlhe40 is required in vivo in a T cell-intrinsic manner, where it positively regulates the production of GM-CSF and negatively regulates the production of IL-10. In vitro, GM-CSF secretion is selectively abrogated in polarized Bhlhe40−/− TH1 and TH17 cells, and these cells show increased production of IL-10. Blockade of IL-10 receptor in Bhlhe40−/− mice renders them susceptible to EAE. These findings identify Bhlhe40 as a critical regulator of autoreactive T-cell pathogenicity.
- 3 April 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 1-13
Open AccessBhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation
TH1 and TH17 cells mediate neuroinflammation in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Pathogenic TH cells in EAE must produce the pro-inflammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF). TH cell pathogenicity in EAE is also regulated by cell-intrinsic production of the immunosuppressive cytokine interleukin 10 (IL-10). Here we demonstrate that mice deficient for the basic helix–loop–helix (bHLH) transcription factor Bhlhe40 (Bhlhe40−/−) are resistant to the induction of EAE. Bhlhe40 is required in vivo in a T cell-intrinsic manner, where it positively regulates the production of GM-CSF and negatively regulates the production of IL-10. In vitro, GM-CSF secretion is selectively abrogated in polarized Bhlhe40−/− TH1 and TH17 cells, and these cells show increased production of IL-10. Blockade of IL-10 receptor in Bhlhe40−/− mice renders them susceptible to EAE. These findings identify Bhlhe40 as a critical regulator of autoreactive T-cell pathogenicity.
- Open Access
- 6 February 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56203
Transiently Transfected Purine Biosynthetic Enzymes Form Stress Bodies
It has been hypothesized that components of enzymatic pathways might organize into intracellular assemblies to improve their catalytic efficiency or lead to coordinate regulation. Accordingly, de novo purine biosynthesis enzymes may form a purinosome in the absence of purines, and a punctate intracellular body has been identified as the purinosome. We investigated the mechanism by which human de novo purine biosynthetic enzymes might be organized into purinosomes, especially under differing cellular conditions. Irregardless of the activity of bodies formed by endogenous enzymes, we demonstrate that intracellular bodies formed by transiently transfected, fluorescently tagged human purine biosynthesis proteins are best explained as protein aggregation.
- 6 February 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56203
Open AccessTransiently Transfected Purine Biosynthetic Enzymes Form Stress Bodies
It has been hypothesized that components of enzymatic pathways might organize into intracellular assemblies to improve their catalytic efficiency or lead to coordinate regulation. Accordingly, de novo purine biosynthesis enzymes may form a purinosome in the absence of purines, and a punctate intracellular body has been identified as the purinosome. We investigated the mechanism by which human de novo purine biosynthetic enzymes might be organized into purinosomes, especially under differing cellular conditions. Irregardless of the activity of bodies formed by endogenous enzymes, we demonstrate that intracellular bodies formed by transiently transfected, fluorescently tagged human purine biosynthesis proteins are best explained as protein aggregation.